Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Charles Baker-Glenn"'
Publikováno v:
Drug Discovery Today. 27:134-150
Despite the devastating impact of many lung diseases on human health, there is still a significant unmet medical need in respiratory diseases, for which inhaled delivery represents a crucial strategy. More guidance on how to design and carry out mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd52519089dcbbbea67cae84a75d499
https://doi.org/10.1016/j.drudis.2021.09.005
https://doi.org/10.1016/j.drudis.2021.09.005
Autor:
Maurizio Civelli, Anna Rita Pisano, Gino Villetti, Hervé Van de Poël, Francesco Amadei, Vanessa Pitozzi, Carmelida Capaldi, Gabriele Amari, Alice Pappani, Michela Salvadori, Fanti Renato De, Paola Puccini, Valentina Cenacchi, Wesley Blackaby, Maurizio Delcanale, Riccardo Patacchini, Kevin Nash, Andrea Rizzi, Gessica Marchini, Maria Pittelli, Marcello Trevisani, Elisabetta Armani, Charles Baker-Glenn
Publikováno v:
Journal of Medicinal Chemistry. 64:9100-9119
In this paper, we report the discovery of dual M3 antagonist-PDE4 inhibitor (MAPI) compounds for the inhaled treatment of pulmonary diseases. The identification of dual compounds was enabled by the intuition that the fusion of a PDE4 scaffold derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08490f25233eb81069f2d4eba3b83b28
https://doi.org/10.1021/acs.jmedchem.1c00204
https://doi.org/10.1021/acs.jmedchem.1c00204
The aldol products derived from sulfur- or selenium containing acceptors were prepared by kinetic resolution in the presence of antibody 84G3 with enantiomeric excesses ranging from 56 to 70%. Much higher level of enantioselectivity was obtained (ena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d97d545a1fd68a3fa9e8381d781e5e7a
https://ora.ox.ac.uk/objects/uuid:4d6d5fb6-859c-41b9-966e-9adc45a8b5b6
https://ora.ox.ac.uk/objects/uuid:4d6d5fb6-859c-41b9-966e-9adc45a8b5b6
Autor:
John Atherall, Bryan K. Chan, Tracy Kleinheinz, Daniel G. Shore, Andrew D. Medhurst, Huifen Chen, Haitao Zhu, Anthony A. Estrada, Sara L. Dominguez, Kimberly Scearce-Levie, Jason Drummond, Alan Beresford, Kevin M. Nash, Zejuan Sheng, Mark Stuart Chambers, Zachary Kevin Sweeney, Andrew Gill, Claire E. Le Pichon, Shuo Zhang, Charles Baker-Glenn, John Moffat, Hervé Van de Poël, Daniel J. Burdick, Xingrong Liu
Publikováno v:
ACS Medicinal Chemistry Letters. 4:85-90
The modulation of LRRK2 kinase activity by a selective small molecule inhibitor has been proposed as a potentially viable treatment for Parkinson's disease. By using aminopyrazoles as aniline bioisosteres, we discovered a novel series of LRRK2 inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ca6d12fe121b38c5bfe4ca1517ec13
https://doi.org/10.1021/ml3003007
https://doi.org/10.1021/ml3003007
Autor:
Mike W. Pleasants, Gerald Pattenden, Andrew Plumridge, Malcolm Stratford, David B. Archer, Michaela Novodvorska, Charles Baker-Glenn
Publikováno v:
International Journal of Food Microbiology. 157(3):375-383
Moulds are able to cause spoilage in preserved foods through degradation of the preservatives using the Pad-decarboxylation system. This causes, for example, decarboxylation of the preservative sorbic acid to 1,3-pentadiene, a volatile compound with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f396bef46085adfec91974354079fb04
Autor:
Gerald Pattenden, Iain H. Moal, James L. Melville, Jonathan D. Hirst, Peter E. Shaw, Charles Baker-Glenn
Publikováno v:
Biophysical Journal. 92:3862-3867
By the use of x-ray structures and flexible docking, we have developed the first in silico ligand-based view of the structural determinants of the binding of small molecule mimics of gelsolin, natural products bound to actin. Our technique highlights
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b1c71887736c260206bfa10e8de9625
https://doi.org/10.1529/biophysj.106.103580
https://doi.org/10.1529/biophysj.106.103580
Autor:
Janice Saxton, Iain H. Moal, Peter E. Shaw, Emma E. Vincent, Charles Baker-Glenn, Gerald Pattenden, Jonathan D. Hirst
Publikováno v:
Cellular and Molecular Life Sciences. 64:487-497
Several marine macrolide toxins act as potent and specific actin-severing molecules. Recent elucidation of their stereochemistries and modes of interaction with actin has allowed the syntheses of bioactive analogues. Here we used synthetic analogues
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662d0dd8e3811afe0e0cbcd5817da845
https://doi.org/10.1007/s00018-007-6427-1
https://doi.org/10.1007/s00018-007-6427-1
Autor:
Panayiotis A. Procopiou, Mark Ruston, Andrew A. Gray, Anthony G. M. Barrett, Charles Baker-Glenn
Publikováno v:
Tetrahedron Letters. 46:7427-7430
The use of potassium trimethylsilanolate as base to induce elimination of potassium arenesulfinate from alkyl aryl sulfones to produce E-alkenes is described. The reaction was appropriate for substrates containing a benzyl or allyl group α to the su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::925723deaa3a7a9b62c304e613b53f28
https://doi.org/10.1016/j.tetlet.2005.08.097
https://doi.org/10.1016/j.tetlet.2005.08.097
Autor:
Claire E. Le Pichon, Sara L. Dominguez, Reina N. Fuji, Anthony A. Estrada, Daniel J. Burdick, Michael Flagella, Charles Baker-Glenn, Huifen Chen, Andrew D. Medhurst, Shuo Zhang, Seth F. Harris, Kimberly Scearce-Levie, Zejuan Sheng, Jennafer Dotson, Mark Stuart Chambers, Timothy P. Heffron, John Moffat, Bryan K. Chan, Susan Wong, Tracy Kleinheinz, Daniel G. Shore, Xingrong Liu, Jason Drummond, Jason Halladay, Joseph P. Lyssikatos, Alan Beresford, Kevin M. Nash, Haitao Zhu, Xiaolin Zhang, Andrew Gill, Donna W. Lee, Zachary Kevin Sweeney
Publikováno v:
Journal of medicinal chemistry. 57(3)
Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is one of the most compelling targets for a potential disease-modifying Parkinson's disease therapy. Herein, we disclose structurall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::780d9bdab89a7e52942ce418716e6ff9
https://pubmed.ncbi.nlm.nih.gov/24354345
https://pubmed.ncbi.nlm.nih.gov/24354345
Autor:
Jennafer Dotson, John Moffat, Timothy P. Heffron, Huifen Chen, Seth F. Harris, Alan Beresford, Kevin M. Nash, Daniel J. Burdick, Janet Gunzner-Toste, Andrew Gill, Reina N. Fuji, Sean P. Flynn, Andrew D. Medhurst, Anthony A. Estrada, Charles Baker-Glenn, Xingrong Liu, Kimberly Scearce-Levie, Claire E. Le Pichon, Joseph P. Lyssikatos, Mark Stuart Chambers, Shumei Wang, Haitao Zhu, Xiaolin Zhang, Bryan K. Chan, Sara L. Dominguez, Antonio G. DiPasquale, Naimisha Trivedi, Tracy Kleinheinz, Guiling Zhao, Zejuan Sheng, Xiao Ding, Daniel G. Shore, Jason Drummond, Susmith Mukund, Michael Flagella, Donna W. Lee, Zachary Kevin Sweeney, Shuo Zhang, Thuy B. Tran
Publikováno v:
Journal of medicinal chemistry. 55(22)
There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinson's disease p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9937f2633824bb31053bc7e58e6690c1
https://pubmed.ncbi.nlm.nih.gov/22985112
https://pubmed.ncbi.nlm.nih.gov/22985112